Jeffrey Sumpolec, M.A. LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 18333 Dolan Way Ste 205, Canyon Country, CA 91387 Phone: 540-842-4999 |
Amanda Hawes Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 17961 Lost Canyon Rd Unit 51, Canyon Country, CA 91387 Phone: 626-321-7675 |
Hannah Cox Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 27225 Camp Plenty Rd Ste 7d, Canyon Country, CA 91351 Phone: 818-927-1284 |
Jeremy M Sforza Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 28085 Whites Canyon Rd, Apt# 91, Canyon Country, CA 91351 Phone: 661-670-7848 |
Katherine Orellana-lopez Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 16944 Shinedale Dr, Canyon Country, CA 91387 Phone: 805-822-3060 |
Richard D Hecht, LMFT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 14708 Sundance Pl, Canyon Country, CA 91387 Phone: 818-631-2218 |
Ms. Claudia Ivoen Rodriguez, MSW, ASW Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 19059 Vicci St, Canyon Country, CA 91351 Phone: 805-377-5424 |
News Archive
Researchers quantified the general VE achieved in the population of Norway, with the realized mixture of vaccine types, current population characteristics, and epidemic trajectory and directly estimated VE across vaccine types and age groups.
New research sheds light on a neural growth factor called proBDNF, finding that it is present and potentially active during the perinatal period when the brain's circuitry and memory-encoding regions are being refined.
It's hard to think of scientists in laboratories working toward solutions for medical problems without mice or other laboratory animals, but animals' roles in at least one major research laboratory may soon be minimal.
Today, Lung Cancer Alliance (LCA) announced that the Department of Veterans Affairs (VA) has agreed to move forward on CT screening for veterans at high risk for lung cancer. This was communicated to Laurie Fenton Ambrose, LCA President & CEO in written correspondence by VA Under Secretary for Health Dr. Robert A. Petzel.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
› Verified 1 days ago